[Remote] AI Scientist at Abata Therapeutics

London, England, United Kingdom

Apply Now

Not SpecifiedCompensation

Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Artificial IntelligenceIndustries

Requirements

PhD in Computer Science/Artificial Intelligence/ Machine Learning or related technical fields
Track record of AI Innovation demonstrated through publications in Artificial Intelligence/Machine Learning or projects applying them to interdisciplinary fields
3+ years of work experience post-PhD in an industrial setting or equivalent academic post-doctoral experience
Experienced in developing and implementing new deep learning methods
Experienced in PyTorch, training and inference of large models on GPUs
Peer reviewed published research in developing AI methods (example in ICLR, NeurIPS, ICML, Nature, Science, Cell etc.)
Experience in working at the interface of AI and Biology
Experience working on large scale distributed training and inference
Experience communicating research for public audiences of peers
Participation in the open-source community
Scientifically curious with an interest to work on interdisciplinary teams

Responsibilities

Initiate and drive new projects that advance the SOTA AI models for biology impacting drug discovery and clinical development
Work closely with interdisciplinary experts with world-class biology, drug discovery, and clinical expertise

Skills

Deep Learning

Artificial Intelligence

Machine Learning

Drug Discovery

Protein Therapeutics

Antibody Therapeutics

Generative AI

Foundation Models

AI Innovation

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free